Logo

Michael Dalling, Larry Stambaugh

Feb 28, 2008
Premium
Benitec said this week that Michael Dalling has resigned as non-executive director of the board.
 
Dalling has been a Benitec director since March 2006, the company said.
 
 
Arrowhead Research said that Larry Stambaugh has stepped down as CEO of Arrowhead subsidiaries Insert Therapeutics and Calando Pharmaceuticals (see related story, this issue).
 
He will remain a consultant to Arrowhead, the company said.
 
Stambaugh’s departure comes amid a corporate restructuring that includes the merger of the two subsidiaries, which remains subject to Arrowhead shareholder approval.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.